Tau Oligomers in Sera of Patients with Alzheimer’s Disease and Aged Controls

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Alzheimer's Disease

• Publication date

  2017-04-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.3233/JAD-170048PMID 28453485
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tau oligomers in cerebrospinal fluid in Alzheimer's disease

  2017cited by this paper
• Clearance systems in the brain-implications for Alzheimer disease.

  2015cited by this paper
• Amyloid β Oligomers Disrupt Blood–CSF Barrier Integrity by Activating Matrix Metalloproteinases

  2015cited by this paper
• Clearance systems in the brain—implications for Alzheimer disease

  2015cited by this paper
• Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles

  2014cited by this paper
• Proteins Recruited to Exosomes by Tau Overexpression Implicate Novel Cellular Mechanisms Linking Tau Secretion with Alzheimer's Disease

  2014cited by this paper
• Neuronal activity regulates extracellular tau in vivo

  2014cited by this paper
• Highly potent soluble amyloid-β seeds in human Alzheimer brain but not cerebrospinal fluid.

  2014cited by this paper
• Cerebrospinal fluid biomarkers of Alzheimer’s disease

  2014cited by this paper
• Impairment of Glymphatic Pathway Function Promotes Tau Pathology after Traumatic Brain Injury

  2014cited by this paper
• Unconventionally secreted effectors of two filamentous pathogens target plant salicylate biosynthesis

  2014cited by this paper
• Blood–brain-barriers in aging and in Alzheimer’s disease

  2013cited by this paper
• Sustained choroid plexus function in human elderly and Alzheimer’s disease patients

  2013cited by this paper
• Physiological release of endogenous tau is stimulated by neuronal activity

  2013cited by this paper
• Plasma tau levels in Alzheimer's disease

  2013cited by this paper
• A Possible Role for CSF Turnover and Choroid Plexus in the Pathogenesis of Late Onset Alzheimer's Disease

  2012cited by this paper
• Platelet Tau Pattern Correlates with Cognitive Status in Alzheimer's Disease

  2012cited by this paper
• Pathological Alteration in the Choroid Plexus of Alzheimer’s Disease: Implication for New Therapy Approaches

  2012cited by this paper
• Constitutive secretion of tau protein by an unconventional mechanism.

  2012cited by this paper
• Structure and Pathology of Tau Protein in Alzheimer Disease

  2012cited by this paper
• Identification of oligomers at early stages of tau aggregation in Alzheimer's disease

  2012cited by this paper
• Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles

  2012cited by this paper
• What is the pathological significance of tau oligomers?

  2012cited by this paper
• Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament.

  2012cited by this paper
• Tau is reduced in AD plasma and validation of employed ELISA methods.

  2012cited by this paper
• The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Are Tangles as Toxic as They Look?

  2011cited by this paper
• CSF biomarkers for Alzheimer's disease: current utility and potential future use.

  2011cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Human Platelets Tau: A Potential Peripheral Marker for Alzheimer's Disease

  2011cited by this paper
• Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.

  2011cited by this paper
• Preparation and characterization of neurotoxic tau oligomers.

  2010cited by this paper
• Age-Dependent Impairment of Cognitive and Synaptic Function in the htau Mouse Model of Tau Pathology

  2009cited by this paper
• Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis

  2007cited by this paper
• Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy

  2007cited by this paper
• Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model.

  2007cited by this paper
• Tau protein as a serum marker of brain damage in mild traumatic brain injury: Preliminary results

  2006cited by this paper
• Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force

  2006cited by this paper
• The choroid plexus in the rise, fall and repair of the brain

  2005cited by this paper
• The choroid plexus-cerebrospinal fluid system: from development to aging.

  2005cited by this paper
• The choroid plexus removes beta-amyloid from brain cerebrospinal fluid.

  2005cited by this paper
• The Choroid Plexus Removes β-Amyloid from Brain Cerebrospinal Fluid

  2005cited by this paper
• Infectious disease: Unravelling SARS lethality

  2005cited by this paper
• Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function

  2005cited by this paper
• Unconventional protein secretion: membrane translocation of FGF-2 does not require protein unfolding

  2004cited by this paper
• CHOROID PLEXUS, AGEING OF THE BRAIN, AND ALZHEIMER'S DISEASE

  2003cited by this paper
• Choroid plexus, aging of the brain, and Alzheimer's disease.

  2003cited by this paper
• Serum Tau Protein Level as a Marker of Axonal Damage in Acute Ischemic Stroke

  2002cited by this paper
• Ageing choroid plexus‐cerebrospinal fluid system

  2001cited by this paper
• The molecular bases of Alzheimer's disease and other neurodegenerative disorders.

  2001cited by this paper
• Tauopathy in Drosophila: Neurodegeneration Without Neurofibrillary Tangles

  2001cited by this paper
• Neurofibrillary tangles and tau phosphorylation.

  2001cited by this paper
• Morphological alterations of the choroid plexus in late-onset Alzheimer’s disease

  2000cited by this paper
• Mild Cognitive Impairment Clinical Characterization and Outcome

  1999cited by this paper
• Natural anticoagulants, aging, and thromboembolism.

  1998cited by this paper
• [The value of new diagnostic techniques in Alzheimer's disease].

  1992cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Divergent disruptive effects of soluble recombinant tau assemblies on synaptic plasticity in vivo

  2025cites this paper
• Effects of pressing moxibustion at Baihui (GV 20) and Guanyuan (CV 4) on cognitive impairment and serum levels of Aβ1-42, tau, P-tau in patients with mild to moderate Alzheimer's disease.

  2024cites this paper
• Generation of nanobodies with conformational specificity for tau oligomers that recognize tau aggregates from human Alzheimer's disease samples

  2024cites this paper
• Differential accumulation of human β-amyloid and tau from enriched extracts in neuronal and endothelial cells.

  2024cites this paper
• Clathrin mediated endocytosis in Alzheimer's disease: cell type specific involvement in amyloid beta pathology.

  2024cites this paper
• Tau Oligomers as Pathogenic Seeds: Preparation, Characterization, and Propagation In Vitro and In Vivo.

  2024cites this paper
• Alzheimer’s Disease and Its Possible Evolutionary Origin: Hypothesis

  2023cites this paper
• A glimpse into the structural properties of α‐synuclein oligomers

  2023cites this paper
• Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies

  2023cites this paper
• siRNA drug delivery across the blood-brain barrier in Alzheimer's Disease.

  2023cites this paper
• Structure-specific amyloid precipitation in biofluids

  2022cites this paper
• Heterogeneous Tau Oligomers as Molecular Targets for Alzheimer’s Disease and Related Tauopathies

  2022cites this paper
• The prion-like transmission of tau oligomers via exosomes

  2022cites this paper
• Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.

  2022cites this paper
• Tau Internalization: A Complex Step in Tau Propagation.

  2021cites this paper
• Inflammation: major denominator of obesity, Type 2 diabetes and Alzheimer's disease-like pathology?

  2020cites this paper
• Inhibition of Aβ aggregates in Alzheimer's disease by epigallocatechin and epicatechin-3-gallate from green tea.

  2020cites this paper
• The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer’s Disease (AD)

  2019cites this paper
• Tau-Reactive Endogenous Antibodies: Origin, Functionality, and Implications for the Pathophysiology of Alzheimer's Disease

  2019cites this paper
• Distinct Conformations, Aggregation and Cellular Internalization of Different Tau Strains

  2019cites this paper
• Animal Experimentation: Working Towards a Paradigm Change

  2019cites this paper
• Animal Research for Alzheimer Disease: Failures of Science and Ethics

  2019cites this paper
• Surface tension and intrinsic amyloid fluorescence of serum and cerebrospinal fluid samples in Alzheimer´s disease.

  2019cites this paper
• PATHOLOGICAL TAU AS A CAUSE, AND CONSEQUENCE, OF CELLULAR DYSFUNCTION

  2019cites this paper
• Heme Oxygenase 1 Induces Tau Oligomer Formation and Synapse Aberrations in Hippocampal Neurons

  2018cites this paper
• Circadian wheel running behavior is altered in an APP/E4 mouse model of late onset Alzheimer's disease.

  2017cites this paper
• Tau protein and its variants in the diagnosis of Alzheimer's disease

  2017cites this paper
• Michala Krestová Tau protein and its variants in the diagnosis of Alzheimer ’ s disease

  2017cites this paper
• Cerebral Hypoperfusion and Other Shared Brain Pathologies in Ischemic Stroke and Alzheimer’s Disease

  2017cites this paper
• Tau Diagnostics and Clinical Studies

  2017cites this paper